39432714 2025-01-01 2025-12-31 39432714 2025-01-01 2025-12-31 2 39432714 2025-01-01 2025-12-31 memberOfBoardIdentifier_executive_board_1 39432714 2025-01-01 2025-12-31 memberOfBoardIdentifier_board_of_director_1 39432714 2025-01-01 2025-12-31 memberOfBoardIdentifier_board_of_director_2 39432714 2025-01-01 2025-12-31 memberOfBoardIdentifier_board_of_director_3 39432714 2025-01-01 2025-12-31 memberOfBoardIdentifier_board_of_director_4 39432714 2025-01-01 2025-12-31 1 39432714 2024-01-01 2024-12-31 39432714 2025-12-31 39432714 2024-12-31 39432714 2025-01-01 fsa:ContributedCapitalMember 39432714 2025-01-01 fsa:RetainedEarningsMember 39432714 2025-01-01 39432714 2025-01-01 2025-12-31 fsa:ContributedCapitalMember 39432714 2025-01-01 2025-12-31 fsa:RetainedEarningsMember 39432714 2025-12-31 fsa:ContributedCapitalMember 39432714 2025-12-31 fsa:RetainedEarningsMember 39432714 2025-01-01 fsa:AcquiredPatentsMember 39432714 2025-12-31 fsa:AcquiredPatentsMember 39432714 2025-01-01 2025-12-31 fsa:AcquiredPatentsMember 39432714 2025-01-01 fsa:OtherInvestmentsMember 39432714 2025-12-31 fsa:OtherInvestmentsMember iso4217:DKK pure Årsrapport 33771231 PricewaterhouseCoopers Statsautoriseret Revisionspartnerselskab Strandvejen 44 2900 Hellerup 2025-01-01 2024-01-01 2025-12-31 2024-12-31 PricewaterhouseCoopers Statsautoriseret Revisionspartnerselskab 33771231 Regnskabsklasse B Andre erklæringer uden sikkerhed 2026-06-17 Niels Jonas Heilskov Graversen The Executive Board and Board of Directors have today considered and adopted the Annual Report of DeLiver Pharma ApS for the financial year 1 January - 31 December 2025. The Annual Report is prepared in accordance with the Danish Financial Statements Act. The Company complies with the exemption provisions governing the omission to have its Financial Statements audited. In our opinion the Financial Statements give a true and fair view of the financial position at 31 December 2025 of the Company and of the results of the Company operations for 2025. We recommend that the Annual Report be adopted at the Annual General Meeting. Faaborg 2026-06-17 Niels Jonas Heilskov Graversen Manager Jens Kristian Damsgaard Holger Jon Møller Niels Jonas Heilskov Graversen Chairman Søren Kragh Moestrup To the Management of DeLiver Pharma ApSWe have compiled the Financial Statements of DeLiver Pharma ApS for the financial year 1 January - 31 December 2025 on the basis of the Company’s accounting records and other information you have provided.The Financial Statements comprise income statement, balance sheet, statement of changes in equity and notes, including a summary of significant accounting policies.We performed our work in accordance with ISRS 4410, Engagements to Compile Financial Information.Based on our professional expertise, we have assisted you with the preparation and presentation of the Financial Statements in accordance with the Danish Financial Statements Act. We have complied with relevant provisions of the Danish Act on Approved Auditors and Audit Firms and the International Ethics Standards Board for Accountants’ International Code of Ethics for Professional Accountants (IESBA Code), including the principles of integrity, objectivity, professional competence and due care.The Financial Statements and the accuracy and completeness of the information forming the basis of the compilation of the Financial Statements are your responsibility.As an engagement to compile financial information is not an assurance engagement, we are under no duty to verify the accuracy or completeness of the information you provided to us to compile the Financial Statements. Accordingly, we express no audit opinion or review opinion as to whether the Financial Statements have been prepared in accordance with the Danish Financial Statements Act. Odense 2026-06-17 PricewaterhouseCoopersStatsautoriseret Revisionspartnerselskab 33771231 Peter Krogh Johansen Martin Mose Thomsen State Authorised Public Accountant State Authorised Public Accountant mne45868 mne52590 DeLiver Pharma ApS Sanatorievej 8 5600 Faaborg 39432714 Odense Munkebjergvænget 1, 3. og 4. sal 5230 Odense M -20487 -10302 11380 11380 -31867 -21682 -31867 -21682 0 0 -31867 -21682 -31867 -21682 53525 64906 53525 64906 12500 12500 12500 12500 66025 77406 0 264 0 264 110338 128418 110338 128682 176363 206088 260000 260000 -96779 -64912 163221 195088 11499 11000 1643 0 13142 11000 13142 11000 176363 206088 260000 -64912 195088 0 -31867 -31867 260000 -96779 163221 The company has contracted out its patents to OncoSpear ApS. The company's primary activity going forward is maintaining the patent portfolio, while active development of pharmaceuticals in the company is not pursued. The activities in the company are relatively few and the expenses can largely be passed on to the licensee. Furthermore it is expected that income will arise from the license agreement at a later stage. Until enough income is generated from the license agreement, the company's operation will be secured through capital contributions from the owners.On this basis it is the management's assessment that the capital is sufficient to be able to maintain operations. In accordance with this management submits the annual report under the assumption of the company's continued operation. The purpose of the company is the development and sale of technological products and other related business. 0 0 11380 11380 11380 11380 381223 381223 316318 11380 327698 53525 12500 12500 12500 There are no security and contingent liabilities at 31 December 2025. The Annual Report of DeLiver Pharma ApS for 2025 has been prepared in accordance with the provisions of the Danish Financial Statements Act applying to enterprises of reporting class B as well as selected rules applying to reporting class C.The accounting policies applied remain unchanged from last year.The Financial Statements for 2025 are presented in DKK. Recognition and measurementRevenues are recognised in the income statement as earned. Furthermore, value adjustments of financial assets and liabilities measured at fair value or amortised cost are recognised. Moreover, all expenses incurred to achieve the earnings for the year are recognised in the income statement, including depreciation, amortisation, impairment losses and provisions as well as reversals due to changed accounting estimates of amounts that have previously been recognised in the income statement.Assets are recognised in the balance sheet when it is probable that future economic benefits attributable to the asset will flow to the Company, and the value of the asset can be measured reliably.Liabilities are recognised in the balance sheet when it is probable that future economic benefits will flow out of the Company, and the value of the liability can be measured reliably.Assets and liabilities are initially measured at cost. Subsequently, assets and liabilities are measured as described for each item below. Other external expensesOther external expenses comprise expenses for office expenses, etc. Gross lossWith reference to section 32 of the Danish Financial Statements Act, gross profit/loss comprises of other external expenses. Amortisation, depreciation and impairment lossesAmortisation, depreciation and impairment losses comprise amortisation and impairment of intangible assets. Tax on profit/loss for the yearTax for the year consists of current tax for the year and changes in deferred tax for the year. The tax attributable to the profit for the year is recognised in the income statement, whereas the tax attributable to equity transactions is recognised directly in equity. Intangible fixed assetsPatents and licences are measured at the lower of cost less accumulated amortisation and recoverable amount. Patents are amortised over the remaining patent period, and licences are amortised over the licence period; however not exceeding 12 year. Impairment of fixed assetsThe carrying amounts of intangible assets are reviewed on an annual basis to determine whether there is any indication of impairment other than that expressed by amortisation.If so, the asset is written down to its lower recoverable amount. Fixed asset investmentsInvestments which are not traded in an active market are measured at the lower of cost and recoverable amount. Receivables are measured in the balance sheet at the lower of amortised cost and net realisable value, which corresponds to nominal value less provisions for bad debts. Deferred tax assets and liabilitiesDeferred income tax is measured using the balance sheet liability method in respect of temporary differences arising between the tax bases of assets and liabilities and their carrying amounts for financial reporting purposes on the basis of the intended use of the asset and settlement of the liability, respectively.Deferred tax assets, including the tax base of tax loss carry-forwards, are measured at the value at which the asset is expected to be realised, either by elimination in tax on future earnings or by set-off against deferred tax liabilities within the same legal tax entity.Deferred tax is measured on the basis of the tax rules and tax rates that will be effective under the legislation at the balance sheet date when the deferred tax is expected to crystallise as current tax. Any changes in deferred tax due to changes to tax rates are recognised in the income statement or in equity if the deferred tax relates to items recognised in equity. Debts are measured at amortised cost, substantially corresponding to nominal value.